Compare WCCB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WCCB | ASMB |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.6M | 512.1M |
| IPO Year | 2026 | 2010 |
| Metric | WCCB | ASMB |
|---|---|---|
| Price | $63.00 | $20.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $69.50 | $52.00 |
| AVG Volume (30 Days) | 61.9K | ★ 199.6K |
| Earning Date | 09-23-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.91 | $19.30 |
| 52 Week High | $63.89 | $39.71 |
| Indicator | WCCB | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 35.67 |
| Support Level | $59.68 | $19.30 |
| Resistance Level | $63.89 | $21.93 |
| Average True Range (ATR) | 0.99 | 1.02 |
| MACD | 0.20 | 0.26 |
| Stochastic Oscillator | 68.07 | 23.05 |
West Coast Community Bancorp is a bank holding company. Through its banking subsidiary, it offers a full range of commercial and personal banking services to residents and businesses in Santa Cruz County and adjacent Monterey, San Luis Obispo, and Santa Clara counties. Its products and service offerings include mobile banking, credit and debit cards, treasury management, deposit products, such as checking, savings, and term certificate accounts, and lending products such as commercial, commercial real estate, construction, multifamily, municipal, asset-backed loans, etc. Its lending products also include various government guarantee programs such as Small Business Administration (SBA) and 504 programs, as well as U.S. Department of Agriculture (USDA) programs.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.